Palvella receives European patent for QTORIN rapamycin formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
March 16, 2026 7:30 AM EDTPatent strengthens global intellectual property protection for QTORIN rapamycin, Palvellas lead product candidate from the QTORIN platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies
Patent protection extends into 2038
QTORIN rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval
There are currently no approved therapies in the European Union for microcystic lymphatic malformationsÂ
WAYNE, Pa., March 16, 2026 (GLOBE NEWSWIRE) --... More
